Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
BioMarin Pharmaceutical (DE:BM8)
FRANKFURT:BM8
RESEARCH TOOLSreports
Holding DE:BM8?
Track your performance easily
BM8 Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€58.16 - €90.52
Previous Close€59.1
Volume0.00
Average Volume (3M)275.00
Market Cap
€11.55B
Enterprise Value€11.23B
Total Cash (Recent Filing)$930.44M
Total Debt (Recent Filing)$594.63M
Price to Earnings (P/E)―
Beta0.21
Next Earnings
Feb 20, 2025EPS Estimate
€0.52Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding190,583,016
10 Day Avg. Volume134
30 Day Avg. Volume275
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)2.05
Price to Sales (P/S)4.29
Price to Cash Flow (P/CF)13.30
P/FCF Ratio14.70
Enterprise Value/Market CapN/A
Enterprise Value/Revenue4.08
Enterprise Value/Gross Profit5.90
Enterprise Value/Ebitda22.27
Forecast
1Y Price Target
€94.09Price Target Upside55.78% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering27
BioMarin Pharmaceutical News
Bulls Say, Bears Say
Bulls Say
Financial PerformanceManagement delivered a strong quarter, leading to 2024 guidance raise and reiteration of Voxzogo's $5B+ opportunity size.
Product PerformanceVoxzogo's first-mover advantage and broad applicability, combined with BioMarin's global marketing capabilities, limit competitor impact on its market opportunity.
Strategic GrowthThe significant untapped market for Voxzogo should support continued revenue growth, and its broad label allowing for early treatment initiation should help BioMarin to defend market dominance.
Bears Say
Competition And Market ShareThe convenience of TransCon CNP, which is a weekly subcutaneous injection, could be a key competitive advantage as compared to Voxzogo which is a daily subcutaneous injection.
Growth And Market ExpectationsThe company is below its guided compound annual growth rate ranges for 2026 and 2034.
Sales And RevenueVoxzogo's revenue was adversely impacted by destocking, with orders pulled into the previous quarter.
---
BM8 FAQ
What was BioMarin Pharmaceutical’s price range in the past 12 months?
BioMarin Pharmaceutical lowest stock price was €58.16 and its highest was €90.52 in the past 12 months.
What is BioMarin Pharmaceutical’s market cap?
Currently, no data Available
When is BioMarin Pharmaceutical’s upcoming earnings report date?
BioMarin Pharmaceutical’s upcoming earnings report date is Feb 20, 2025 which is in 89 days.
How were BioMarin Pharmaceutical’s earnings last quarter?
BioMarin Pharmaceutical released its earnings results on Oct 29, 2024. The company reported €0.519 earnings per share for the quarter, beating the consensus estimate of €0.501 by €0.018.
Is BioMarin Pharmaceutical overvalued?
According to Wall Street analysts BioMarin Pharmaceutical’s price is currently Undervalued.
Does BioMarin Pharmaceutical pay dividends?
BioMarin Pharmaceutical does not currently pay dividends.
What is BioMarin Pharmaceutical’s EPS estimate?
BioMarin Pharmaceutical’s EPS estimate is €0.52.
How many shares outstanding does BioMarin Pharmaceutical have?
BioMarin Pharmaceutical has 190,583,020 shares outstanding.
What happened to BioMarin Pharmaceutical’s price movement after its last earnings report?
BioMarin Pharmaceutical reported an EPS of €0.519 in its last earnings report, beating expectations of €0.501. Following the earnings report the stock price went down -3.65%.
Which hedge fund is a major shareholder of BioMarin Pharmaceutical?
Among the largest hedge funds holding BioMarin Pharmaceutical’s share is PRIMECAP Management Co. It holds BioMarin Pharmaceutical’s shares valued at 1B.
---
BioMarin Pharmaceutical Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€94.09 (55.78% Upside)
€94.09 (55.78% Upside)
Blogger Sentiment
Bullish
DE:BM8 Sentiment 80%
Sector Average 72%
Sector Average 72%
Insider Transactions
Sold Shares
Worth $350.3K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-27.32%
12-Months-Change
Fundamentals
Return on Equity
6.25%
Trailing 12-Months
Asset Growth
1.38%
Trailing 12-Months
Company Description
BioMarin Pharmaceutical
BioMarin Pharmaceutical, Inc. is a biotechnology company, which engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline include Vosoritide (BMN 111) for Achondroplasia and Valoctocogene Roxaparvovec (BMN 270) for Hemophilia A. The company was founded by John C. Klock, Christopher M. Starr and Grant W. Denison on March 21, 1997 and is headquartered in San Rafael, CA.
---
BM8 Company Deck
---
BM8 Earnings Call
Q3 2024
0:00 / 0:00
---
BM8 Revenue Breakdown
28.98% VIMIZIM
19.42% VOXZOGO
17.37% NAGLAZYME
12.56% PALYNZIQ
21.66% Other
---
BM8 Stock 12 Month Forecast
Average Price Target
€94.09
▲(55.78% Upside)
Technical Analysis
BioMarin Pharmaceutical
―
Alnylam Pharma
―
Vertex Pharmaceuticals
―
Regeneron
―
Neurocrine
―
Best Analysts Covering BM8
1 Year
1 Year Success Rate
22/46 ratings generated profit
1 Year Average Return
-2.60%
assigned a buy rating 25 days ago
Copying Cory Kasimov's trades and holding each position for 1 Year would result in 47.83% of your transactions generating a profit, with an average return of -2.60% per trade.
---